PDF Summary:Everything Is Tuberculosis, by John Green

Why is tuberculosis—a completely curable disease—still killing over 1.6 million people annually? In Everything Is Tuberculosis, best-selling novelist and YouTube educator John Green confronts this troubling paradox, revealing how social inequality, stigma, and systemic failures allow a preventable tragedy to continue. After meeting a teenage TB patient in Sierra Leone, Green embarked on a mission to understand and combat humanity’s deadliest infectious disease.

Our guide distills Green’s exploration of TB’s scientific, historical, and social dimensions into a framework for understanding this global crisis. We discuss his insights into how TB persists along lines of poverty and power, and how a combination of medical innovation, social change, and political will could end the epidemic. We also connect Green’s ideas to sources of hope—from fungi in peat bogs that could yield new antibiotics to lessons from Black medical justice movements—providing other perspectives on how we might respond to this ancient disease.

(continued)...

Green says the contrast between the romanticization of TB in the Victorian era and the way the disease is seen today couldn’t be starker. Modern TB carries intense stigma, especially in the communities where it’s most common. This stigma stems from fear of infection, association with poverty, and misconceptions about how the disease spreads. Green identifies several ways this stigma undermines TB control:

1) People delay seeking diagnosis when shame surrounds the disease. Green shares the story of a young woman who told him she wished she had cancer instead of TB to avoid the profound shame her diagnosis brought. This reluctance to acknowledge symptoms allows the disease to progress and spread to others.

2) People don’t adhere to treatment. Patients may hide their condition and avoid taking medication in public. Since TB treatment requires months of daily medication, this social pressure can lead to incomplete treatment and the development of drug-resistant strains.

3) People experience social isolation, compounds suffering. Green describes how Henry, the boy he met in Sierra Leone, was shunned by his extended family after his diagnosis, with some believing he was “cursed.” This rejection removes essential support systems just when patients need them most.

4) Physical illness combined with social rejection has a psychological impact. Depression and anxiety frequently accompany TB diagnosis, complicating recovery and reducing quality of life.

How Social Stigma Works

Green’s exploration of tuberculosis stigma illustrates what sociologist Erving Goffman identified in Stigma as a “spoiled social identity”—a condition that marks someone as different and less than “normal.” Even family members might reject a TB patient because this stigma threatens the entire family’s social standing. Psychologist Geoff Cohen explains the psychological impact of this rejection: If we don’t feel a sense of social belonging, it triggers biological stress responses that can actually worsen our physical health.

The avoidance behaviors Green identifies—delaying diagnosis, hiding medication—represent what Goffman calls “information control,” where stigmatized individuals try to manage how others perceive them. These behaviors, while understandable as individual coping mechanisms, create serious public health consequences by enabling disease progression and transmission.

Factor #3: Barriers to Health Care Access

Even when people overcome stigma and seek care, Green says numerous barriers block access to effective TB diagnosis and treatment:

1) Geographic barriers. In remote or underserved areas, healthcare facilities may be distant or completely absent. Green explains that for patients in these regions, reaching appropriate care often requires long, expensive journeys that many can’t afford.

2) Financial barriers. Even when facilities exist nearby, poverty forces impossible choices between paying for TB treatment or meeting basic needs like food and shelter. Without universal healthcare coverage or subsidized TB programs, many patients start but cannot complete the lengthy treatment regimen.

3) Diagnostic limitations. Many healthcare settings in high-burden countries lack modern diagnostic tools, relying instead on less accurate methods that might miss cases or fail to identify drug resistance. This means many patients receive inadequate treatment or none at all.

4) Medication access issues. Patent restrictions, high prices, and regulatory hurdles keep life-saving medications from those who need them most. Green recounts the story of Shreya Tripathi, a 19-year-old Indian TB patient who sued her government for access to bedaquiline, a critical medication for drug-resistant TB. Though she won her case, the medication arrived too late to save her life.

5) Healthcare workforce shortages. Many high-TB-burden countries have too few trained healthcare workers, especially in rural areas. Those working in TB care often face overwhelming caseloads with inadequate resources, compromising their ability to provide comprehensive care and follow-up.

Using Math to Understand Challenges to Health Care Access

Mathematical modeling—using mathematical equations to represent and predict real-world phenomena—offers a framework for understanding how seemingly disconnected barriers interact in complex ways. Green’s description of barriers aligns with what these mathematical analyses predict: TB persists because multiple interacting barriers create a system where effective care remains out of reach for millions.

For example, geographic barriers represent more than just physical distance. Models show that as distance from health care facilities increases, the probability of successful treatment doesn’t decrease in a simple linear fashion—it often falls much more rapidly than expected. This occurs because multiple challenges compound: Longer travel distances mean higher transportation costs, more time away from work, and greater physical hardship for already ill patients. Similarly, financial barriers don’t just limit treatment access: Poverty creates feedback loops where poor nutrition increases susceptibility to TB, while treatment costs push families further into poverty.

These mathematical approaches also help explain how the resource limitations of healthcare systems cause interactions between the effectiveness of diagnostic technology and the worker shortages Green cites as a barrier. Models show that introducing better diagnostic tools without addressing workflow and access issues produces minimal impact. (For example, in Mozambique, centralized diagnostic services with limited operating hours resulted in substantial underutilization of molecular diagnostic equipment.) Similarly, staffing shortages constrain care, but models show that task-shifting—training lower-skilled workers to perform specific TB-related tasks—can significantly improve outcomes in areas with limited resources.

Mathematical models are also useful for understanding how medication access interacts with other barriers. Modeling studies show that improving diagnosis without simultaneously improving drug access would reduce TB deaths by just 6%, while addressing both simultaneously could achieve a 20% reduction.

Factor #4: Racialized Medicine

The fourth factor Green identifies is the harmful legacy of racialized medicine—viewing diseases through the lens of race and attributing biological differences based on racial categories. Historically, medical authorities claimed that certain racial groups were inherently more susceptible to TB due to supposed biological weaknesses or moral failings. Green explains how this racialized view diverted attention from the real socioeconomic and environmental factors driving TB transmission. By attributing TB to racial characteristics, medical professionals and policymakers justified neglecting marginalized communities and denying them proper resources.

Green offers an example from Canada and the US, where Indigenous children were forcibly sent to residential schools with overcrowded, poorly ventilated quarters where TB spread rapidly. Rather than addressing these conditions, authorities attributed the high TB rates to an inherent “racial susceptibility” among Indigenous peoples. This racist belief led to deliberate neglect, resulting in staggeringly high mortality rates among these children.

This harmful legacy continues today in more subtle forms, Green argues. It influences which communities receive attention and resources for TB prevention and treatment. He points to disparities in TB rates along racial and ethnic lines in many countries—disparities that reflect social inequities rather than biological differences, yet are sometimes still misinterpreted through a racialized lens. Green contends that overcoming this legacy requires recognizing that TB is fundamentally a disease of poverty and social injustice, not race. Only by addressing the true socioeconomic determinants of TB can we hope to eliminate it as a public health threat.

How Colonial Thinking Still Shapes TB Care

Scholars agree with Green that medical systems have historically weaponized race to justify the neglect of marginalized communities, deliberately reinforcing colonial power structures that still shape healthcare disparities today. The concept of “racial susceptibility” to TB emerged not from scientific evidence, but from colonial ideologies that required justification for oppression. Medical authorities created two versions of racial thinking about TB: Either Indigenous peoples lacked resistance to the disease but could acquire it over time, or they were inherently susceptible and thus perpetually vulnerable. Both theories conveniently shifted responsibility away from the colonial conditions that enabled TB to flourish.

The residential school system in Canada illustrates how racialized medicine facilitated cultural genocide. Records from the Dynevor Indian Hospital in Manitoba reveal that the majority of TB patients admitted between 1908-1934 were Indigenous children. Rather than addressing the overcrowded, unsanitary conditions in such institutions, authorities blamed weaknesses in Indigenous bodies. Today, Indigenous peoples still experience TB rates far higher than non-Indigenous populations. Many remain reluctant to seek care because of historical trauma resulting from abusive practices that were systemically embedded in medical institutions.

This institutional memory of harm persists both in Indigenous communities’ experiences and in the continuing structural biases within healthcare systems that have never been fully dismantled. Similarly, migrants and refugees face TB control policies that reinforce anti-immigrant sentiment and create additional barriers to care.

Scholars say the decolonization of medicine requires more than acknowledging past wrongs. It demands fundamental institutional transformation, like shifting decision-making authority to those most affected by TB, prioritizing funding for locally-identified needs rather than donor agendas, and recognizing expertise in the Global South (rather than marginalizing it in favor of foreign consultants). Medical associations like the American Medical Association have begun addressing their historical roles in establishing racist medical structures through formal apologies and structural changes. But experts emphasize that transformative change must extend beyond symbolic gestures to include rebuilding systems from the ground up.

How Can We End Tuberculosis?

Green outlines a comprehensive approach to ending the TB epidemic, combining medical innovations, social changes, policy adjustments, and individual advocacy. No single strategy will work in isolation—we need action on all fronts.

Medical Approaches: Improve Diagnosis, Treatment, and Prevention

While medicine alone can’t solve the TB crisis, Green highlights several medical advances that could dramatically reduce TB’s toll while we address deeper social issues:

1) Better diagnostic tools. Green describes newer technologies like GeneXpert that can diagnose TB and detect drug resistance in hours, not the weeks required by traditional methods. These tools remain out of reach in many high-burden areas due to cost and infrastructure limitations. Green advocates reduced pricing and versions adapted for resource-limited settings so these life-saving diagnostics can reach those who need them most.

2) Treatment innovations for drug-resistant TB cases. Green spotlights newer medications like bedaquiline that can treat stubborn TB strains that don’t respond to standard antibiotics. He shares how he took on pharmaceutical giant Johnson & Johnson, criticizing their high prices and restrictive patents on bedaquiline. This public pressure campaign succeeded—the company agreed to allow generic manufacturing, slashing the daily treatment cost from $1.50 to $0.50.

(Shortform note: Johnson & Johnson later stated that they had plans to allow generic manufacturing before Green’s pressure campaign mounted. However, the road to broader bedaquiline access was paved with lengthy legal battles where Johnson & Johnson defended its patent rights, delaying cheaper treatment options for years.)

3) Preventive therapy. Green explains that treating latent TB infection—before it becomes active disease—is simpler and requires fewer medications for a shorter time. This approach could significantly reduce new TB cases, particularly among high-risk groups. Yet limited resources often restrict these preventive programs to very narrow populations.

From Peat Bogs to Coral Reefs: Unconventional Avenues in TB Research

While Green focuses on established medical approaches to TB control, research is emerging from unexpected sources—like deep oceans and peat bogs—that could revolutionize how we diagnose and treat this disease. Marine environments have become surprising hunting grounds for TB-fighting compounds. Scientists studying a Great Barrier Reef sponge recently discovered Mycobacterium spongiae, a bacterium that shares 80% of its genetic material with M. tuberculosis and offers a window into TB’s vulnerabilities. Similarly, researchers have created bacteria that replicate the antibiotics naturally produced by corals and effective against multi-resistant TB strains—without harvesting endangered coral species.

Back on land, researchers from the National Institutes of Health have turned to peat bogs—acidic, oxygen-poor environments surprisingly similar to TB lesions in human lungs. By studying fungi that successfully compete with mycobacteria in this harsh environment, scientists have identified three natural substances (patulin, citrinin, and nidulalin A) that disrupt essential processes in TB bacteria. While these specific compounds aren’t suitable for human use, they’ve highlighted promising biochemical pathways for drug development.

Diagnostic innovations can also take cues from the natural world. Scientists studying whales and dolphins have developed techniques to analyze the microorganisms, hormones, DNA, and metabolic byproducts in animals’ exhaled breath or “blow.” These non-invasive methods parallel emerging breath-based diagnostics for human TB, where compounds in exhaled air can potentially identify active infection more quickly than traditional tests.

Even our understanding of treatment challenges is advancing through creative research methods. Scientists have developed an imaging technique that follows antibiotics directly into TB-infected cells, revealing why current treatments must be taken for so long: Some infected cells remain inaccessible to antibiotics, allowing bacteria to escape treatment. This insight could guide development of more efficient medications capable of reaching all infected cells, potentially shortening treatment time and reducing antibiotic resistance.

4) Vaccine development also remains a critical frontier. The current BCG vaccine provides some protection for children against severe forms of TB but offers limited protection for adults. Green notes that research into more effective vaccines for TB continues, but remains underfunded compared to efforts to develop vaccines for other diseases.

(Shortform note: The BCG vaccine isn’t routinely given in the US. While it prevents severe TB in young children, it provides minimal protection for adolescents and adults, with overall effectiveness estimated at just 18%. And while it may protect individuals, it does little to prevent transmission at the population level. The vaccine works particularly poorly in regions closer to the equator, where TB is most prevalent. But developing new vaccines has been challenging due to TB’s complex biology and historical underfunding. The good news is that several candidates now in late-stage trials show approximately 50% efficacy—not perfect, but potentially transformative for a disease that kills over a million people annually.)

Social Approaches: Address Stigma and Social Determinants of Health

Beyond medical interventions, Green champions social strategies that address TB’s root causes:

1) Public education campaigns to fight stigma and misinformation. Green points to successful programs that involve TB survivors in community education, helping normalize the disease and encourage testing. These campaigns emphasize three key messages: TB is curable, not a moral failing; patients quickly become non-infectious with proper treatment; and support rather than rejection helps recovery.

2) Community engagement to strengthen TB control efforts. Programs that train local community members as health educators and treatment supporters have shown impressive results. This approach builds trust, ensures culturally appropriate messaging, and creates vital support systems for TB patients navigating months of treatment.

3) Tackling poverty and malnutrition. Green highlights programs that combine TB treatment with nutritional support, housing assistance, and income-generation opportunities. These comprehensive approaches recognize that medical treatment alone won’t solve the problem if patients return to the same conditions that made them sick in the first place.

4) Improving housing and ventilation to reduce transmission risk. Simple interventions like adding windows or ventilation systems to buildings can significantly reduce airborne TB transmission. In high-burden areas, Green advocates housing policies that establish minimum ventilation standards and limit overcrowding.

5) Educational support to enhance health literacy and outcomes. General education—particularly for women—correlates strongly with better health outcomes across the board, including TB prevention and treatment success. Green sees removing barriers to education as a long-term TB control strategy with multiple benefits.

How Tuberculosis Shaped Modern Architecture

The modernist architectural movement emerged from a revolutionary social idea—that built environments could heal both bodies and societies—in the Victorian era as the TB epidemic was taking hold. Before antibiotics, tuberculosis sanatoriums functioned as both treatment centers and educational institutions. These facilities taught patients a new health-conscious way of living, emphasizing the dangers of poorly ventilated, overcrowded spaces. Their airy designs—with flat roofs, sun terraces for sunbathing, and large windows—became visual manifestations of a new social ideal: environments that promoted healing rather than disease.

But this architectural revolution had a critical limitation. It largely served the privileged. While sanatoriums expanded dramatically in the early 20th century, they were never accessible to everyone. Working-class TB patients couldn’t simply take months away from their jobs and families to recover in isolated facilities. The cultural memory of this era is strong—in Wes Anderson’s film The Grand Budapest Hotel, the hotel evokes the grand European sanatoriums that served wealthy TB patients with serene efficiency, and the “Prussian Grippe” epidemic echoes TB. Yet Anderson’s portrayal, like the modernist movement itself, glosses over uncomfortable questions about who gets left out and left behind.

In recent decades, modernist architecture has become a cultural battleground—criticized from the left for not being radical enough in delivering on its egalitarian promises and from the right for symbolizing a too-radical vision of society. This controversy highlights architecture’s power as a cultural symbol but also its limitations as an agent of structural change. Yet as Hassan Fathy and other “architects of the poor” have demonstrated, architecture can contribute to fighting poverty and malnutrition through projects like affordable housing that empowers communities, urban agriculture projects that improve food security, and public spaces that foster health and community resilience.

Green’s recommendations for programs combining TB treatment with nutritional support, housing assistance, and income-generation opportunities recognize what many architects now understand: that the built environment can either reinforce or help dismantle the socioeconomic conditions that make TB endemic among the poor.

Policy Approaches: Healthcare Systems, Funding, and Political Action

Ultimately, Green argues, ending TB requires policy-level changes:

1) Strengthen healthcare systems. Fragmented, underfunded health systems struggle to provide the consistent, long-term care TB patients require. Green advocates for investments in primary healthcare infrastructure, reliable supply chains for TB medications, and improved laboratory capacity in high-burden countries.

2) Reform medication access policies. Green describes his advocacy for the End Tuberculosis Now Act in the United States, which would authorize increased international assistance for TB elimination. He also pushes for reforms to patent systems and pricing practices that keep essential TB medications unaffordable where they’re needed most.

3) Establish sustainable funding mechanisms. Green criticizes how TB control efforts in many countries rely heavily on international donor funding, creating vulnerability to shifting political priorities and funding cuts. He calls for increased domestic funding for TB programs and innovative financing approaches to ensure sustainability.

When Politics Disrupts the Fight Against TB

The Trump administration dismantled the United States Agency for International Development (USAID) and frozen global TB funding in 2025, demonstrating how fragile these systems remain and illustrating Green’s key policy principles.

First, Green notes that sustainable funding mechanisms are essential. The current patchwork approach—heavily reliant on foreign aid from wealthy nations—creates dangerous vulnerabilities when political winds shift. When USAID’s $406 million annual TB contribution was abruptly halted, diagnostic services closed, medication distribution stopped, and treatment programs collapsed overnight. As Green warns, these disruptions may increase global TB cases by 30% in coming years.

Second, scholars agree with Green that medication access policies need urgent reform. Even when funding is available, patent systems and high prices keep life-saving drugs unaffordable where they’re needed most. Green’s advocacy against pharmaceutical company Johnson & Johnson helped reduce the cost of a critical TB drug from $1.50 to $0.50 per day, but such victories mean little when delivery programs disappear. Similarly, promising research like a $60-million TB study at Harvard has been halted by the Trump administration.

4) Increase cross-sector collaboration. TB control requires coordination across health, housing, education, and social welfare sectors. Green highlights successful models where governments have established multi-sectoral TB committees with the authority and funding to implement comprehensive strategies.

5) Strengthen global solidarity. Green argues that wealthy nations have compelling reasons to support global TB control efforts. Beyond humanitarian concerns, he notes that in our interconnected world, drug-resistant TB anywhere poses a potential threat everywhere. The tools and knowledge to end TB already exist; what’s lacking is the commitment to deploy them equitably.

Policy Lessons From Ecology—and Fungi

Looking at TB through the lens of ecological systems reveals that it’s more than a biological disease. Bronfenbrenner’s Ecological Systems Theory shows how individual health outcomes are shaped by interconnected layers of influence, from close relationships to cultural and economic systems. This approach allows us to view TB within the broader context of human life and global interconnection.

To understand how ecologists think in systems, imagine mycorrhizal networks—underground systems of fungi that connect forest trees beneath the soil. When one tree has abundant resources, the mycorrhizal network can redistribute those resources to areas where they’re scarce. Like these fungal networks, effective global TB control requires systems that facilitate resource sharing across borders. As Green argues, wealthy nations have compelling reasons to support TB control globally, not just for humanitarian purposes, but because drug-resistant TB anywhere threatens people everywhere. True global solidarity in TB control might redistribute both resources and decision-making power to countries with a high burden of the disease, just as mycorrhizal networks recognize the wisdom of local adaptation.

Additionally, applying systems thinking to public health helps us recognize what scholars call the holobiont perspective: understanding that humans exist as complex ecosystems containing both our own cells and trillions of microbes. This reminds us that fighting disease isn’t just about eliminating threats, but about preserving the balance of the systems we rely on. Like mycorrhizal networks that transcend individual plants to support the entire forest ecosystem, TB control that embraces systems thinking can recognize the interconnectedness of all health—human, animal, and environmental—and move toward sustainable solutions to one of humanity’s oldest health challenges.

Individual and Collective Advocacy

Green concludes with a call for action, both on the individual and community level:

1) Become more aware. Green argues that once we understand TB’s devastating impact and the systems perpetuating it, we have a responsibility to act. He shares how his own learning journey transformed into advocacy and encourages readers to similarly translate knowledge into action.

2) Leverage privilege for change. Green acknowledges his position as a bestselling author and internet personality with millions of followers. He describes how he used this platform to pressure pharmaceutical companies and raise awareness about TB. He encourages readers to identify and use whatever privilege or platform they possess to advocate for those without such access.

3) Use community power to amplify individual voices. Green celebrates the “Nerdfighter” community he and his brother Hank have cultivated, describing how their online followers have raised millions for global health initiatives. He argues that collective action—even from those without traditional forms of power—can create significant change when properly organized and directed.

4) Stay committed. Green emphasizes that addressing TB requires long-term dedication, not just short-term campaigns. He draws parallels to other successful public health initiatives, like smallpox eradication, which succeeded through decades of persistent effort.

Green’s message balances urgency with hope. TB’s persistence represents a failure of our global community, but also an opportunity to demonstrate our capacity for collective action and compassion. Green believes that by sharing what we know, using what influence we have, and joining with others, we can end tuberculosis and create a more just global health system in the process.

Storytelling as Revolution

Black Americans have long confronted and resisted what Harriet Washington calls “medical apartheid”: a two-tiered healthcare system where their bodies have been exploited, their suffering minimized, and their needs ignored. Green’s call for individual and collective TB advocacy draws important lessons from these hard-won struggles for medical justice. Just as medical institutions have treated Black patients as expendable—from non-consensual surgeries during slavery to the infamous Tuskegee Syphilis Study where treatment was deliberately withheld from Black men for decades—TB disproportionately affects marginalized people, who are “out of sight and out of mind” for many privileged members of society.

Black advocacy movements have developed effective responses to such medical injustice and invisibility. Scholars like Dorothy Roberts, who examines race as a political construct that has been misrepresented as biological, explain that successful advocacy requires both demanding systemic change and providing for community needs in the present. This means using multiple strategies simultaneously: organizing protests, publishing media, pursuing legal challenges, and building alternative community support systems. Green’s approach to TB advocacy similarly balances confronting institutional failures with creating community-led support systems.

Some of the most effective medical justice campaigns have combined personal storytelling with the ability to see the systemic causes of inequality. When Washington documented medical abuses against Black Americans, she didn’t just catalog horrors: She revealed their structural causes and connected them to ongoing inequities. TB advocacy can learn from these movements by rejecting narratives that blame individuals for their illness and working to provide both immediate care for affected individuals and sustained pressure for structural change—just as reproductive justice movements led by women of color have fought simultaneously for individual bodily autonomy and systemic transformation.

By embracing this dual focus on individual dignity and collective action, TB advocates might work toward creating social and healthcare systems that truly serve everyone. As Green reminds us, TB anywhere is a threat to people everywhere—making advocacy for the most vulnerable a form of advocacy for us all.